{"date":"2025-01-16","count":3,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6467-2025-01-16-1640-bqlq4k","company_id":"6467","company":"泰合","market":"興櫃","industry":"生技醫療","date":"2025-01-16","time":"16:40:32","subject":"公告本公司新藥TAH3311抗血栓口溶膜之美國臨床試驗三期(Pivotal study, 關鍵試驗)完成所有受試者給藥","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：泰合（6467），2025-01-16 16:40，「公告本公司新藥TAH3311抗血栓口溶膜之美國臨床試驗三期(Pivotal study, 關鍵試驗)完成所有受試者給藥」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6564-2025-01-16-1515-1usnbdl","company_id":"6564","company":"安特羅","market":"興櫃","industry":"生技醫療","date":"2025-01-16","time":"15:15:41","subject":"公告本公司財務主管暨公司治理主管、代理發言人、會計主管、稽核主管異動","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：安特羅（6564），2025-01-16 15:15，「公告本公司財務主管暨公司治理主管、代理發言人、會計主管、稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6547-2025-01-16-1511-ackl7x","company_id":"6547","company":"高端疫苗","market":"上櫃","industry":"生技醫療","date":"2025-01-16","time":"15:11:31","subject":"本公司有價證券近期多次達公佈注意交易資訊標準，故公告相關訊息，以利投資人區別暸解","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：高端疫苗（6547），2025-01-16 15:11，「本公司有價證券近期多次達公佈注意交易資訊標準，故公告相關訊息，以利投資人區別暸解」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}